Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin
DiscussionIf successful, this study will create a new paradigm for BU treatment, which could inform World Health Organization policy and practice. A shortened, highly effective, all-oral regimen will improve care of BU patients and will lead to a decrease in hospitalization-related expenses and indirect and social costs and improve treatment adherence. This trial may also provide information on treatment shortening strategies for other mycobacterial infections (tuberculosis, leprosy, or non-tuberculous mycobacteria infections).Trial registrationClinicalTrials.govNCT05169554. Registered on 27 December 2021. (Source: Trials)
Source: Trials - July 8, 2022 Category: Research Source Type: clinical trials
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy
Condition: Buruli Ulcer Interventions: Drug: Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.; Drug: Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks. Sponsors: Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID); Universidad de Zaragoza; Fondation Raoul Follereau; Université d'Abomey-Calavi; Instituto de Salud Carlos III; Fundación Anesvad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2021 Category: Research Source Type: clinical trials
Thermotherapy of Buruli Ulcer at Community Level in the Health District of Akonolinga
Condition: Buruli Ulcer Intervention: Sponsors: Swiss Tropical & Public Health Institute; University Hospital Heidelberg; Centre International de Recherches, d'Enseignements et de Soins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2019 Category: Research Source Type: clinical trials
